Compositions and methods for reducing lactate levels

Patent metadata

Field	Value
Publication number	US-9585958-B2
Application number	US-201414491714-A
Country	US
Kind code	B2
Filing date	Sep 19, 2014
Priority date	Sep 24, 2013
Publication date	Mar 7, 2017
Grant date	Mar 7, 2017

Abstract

The present disclosure provides methods of reducing levels of lactate in a fluid or tissue in an individual. The present disclosure provides pharmaceutical compositions suitable for use in the methods.

First claim

What is claimed is:

1. A method of reducing the level of lactate in a fluid or tissue of an individual, the method comprising administering to the individual an effective amount of:
a) a compound of formula I:

wherein Z 1 is CH, CR 1 or N;
Z 2 is CH, CR 2 or N;
Z 3 is CH, CR 3 or N;
R 1 , R 2 , R 3 , R 4 and R 5 are each independently selected from hydrogen, acyloxy, hydroxy, thiol, acyl, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, substituted alkyl, substituted alkoxy, substituted alkenyl, substituted alkynyl, substituted cycloalkyl, substituted cycloalkenyl, amino, substituted amino, aminoacyl, acylamino, alkaryl, aryl, aryloxy, azido, carboxyl, carboxylalkyl, cyano, halogen, nitro, heteroaryl, heteroaryloxy, heterocyclyl, heterocyclooxy, aminoacyloxy, oxyacylamino, thioalkoxy, substituted thioalkoxy, thioaryloxy, thioheteroaryloxy, —SO-alkyl, —SO-substituted alkyl, —SO-aryl, —SO-heteroaryl, —SO 2 -alkyl, —SO 2 — substituted alkyl, —SO 2 -aryl, —SO 2 -heteroaryl and trihalomethyl; and
R′ and R″ are each independently selected from hydrogen, an alkyl, an aryl, substituted alkyl and substituted aryl;
or
b) a pharmaceutical composition comprising a compound of (a),
and determining the level of lactate in a fluid or tissue of the individual;
wherein said administering reduces the level of lactate in a fluid or tissue in the individual.

2. The method of claim 1 , wherein the fluid is blood or a blood fraction.

3. The method according to claim 1 , wherein the individual is a mammal.

4. The method according to claim 1 , wherein the individual is a human.

5. The method according to claim 1 , wherein an effective amount of the compound is in a range of from 10 μM to 500 mM.

6. The method according to claim 1 , wherein said administering reduces the level of lactate in a fluid or tissue in the individual to less than 5 mM.

7. The method according to claim 1 , wherein said administering increases the blood pH of the individual by at least 0.02 pH units.

8. The method according to claim 1 , wherein the compound is administered in combination with an anti-cancer agent.

9. The method according to claim 8 , wherein the anti-cancer agent is a cancer chemotherapeutic agent.

10. The method of claim 1 ,
wherein the compound selectively binds to lactate and reduces the level of lactate in a tissue or fluid in the individual, thereby treating a disease or disorder associated with elevated lactate in the individual.

11. The method of claim 10 , wherein the tissue or fluid is blood or a blood fraction.

12. The method according to claim 10 , wherein the disease or disorder is lactic acidosis.

13. The method according to claim 10 , wherein the disease or disorder is cancer, non-Hodgkin's lymphoma, Burkitt lymphoma, mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes (MELAS), diabetes mellitus and deafness (DAD), maternally inherited diabetes and deafness (MIDD), glucose-6-phosphatase deficiency, glycogen storage disease type I (GSD I), von Gierke's disease, fructose 1,6-diphosphatase deficiency, pyruvate dehydrogenase deficiency (PDCD), pyruvate carboxylase deficiency, diabetic ketoacidosis, regional hypoperfusion, hepatic disease, shock, sepsis, ethanol toxicity, hemorrhage, hypoxia, hypoperfusion, isoniazid toxicity, phenformin ingestion, metformin ingestion, nucleoside reverse transcriptase inhibitor ingestion, or cyanide ingestion.

14. The method according to claim 1 , wherein the compound is of formula II:

wherein R 1 , R 2 , R 3 , R 4 and R 5 are each independently selected from hydrogen, acyloxy, hydroxy, thiol, acyl, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, substituted alkyl, substituted alkoxy, substituted alkenyl, substituted alkynyl, substituted cycloalkyl, substituted cycloalkenyl, amino, substituted amino, aminoacyl, acylamino, alkaryl, aryl, aryloxy, azido, carboxyl, carboxylalkyl, cyano, halogen, nitro, heteroaryl, heteroaryloxy, heterocyclyl, heterocyclooxy, aminoacyloxy, oxyacylamino, thioalkoxy, substituted thioalkoxy, thioaryloxy, thioheteroaryloxy, —SO-alkyl, —SO-substituted alkyl, —SO-aryl, —SO-heteroaryl, —SO 2 -alkyl, —SO 2 — substituted alkyl, —SO 2 -aryl, —SO 2 -heteroaryl and trihalomethyl; and
R′ and R″ are each independently selected from hydrogen, an alkyl, an aryl, substituted alkyl and substituted aryl.

15. The method according to claim 14 , wherein the compound is:

16. The method according to claim 10 , wherein an effective amount of the compound is in a range of from 10 μM to 500 mM.

17. A method of treating lactic acidosis in an individual, the method comprising:
administering to the individual a pharmaceutical composition comprising an effective amount of a compound of formula III:

and determining the blood lactate level of the individual, wherein the boronic acid compound selectively binds to lactate and treats the lactic acidosis.

18. The method of claim 1 , wherein R 1 , R 2 , R 3 , R 4 and R 5 are each hydrogen.

19. The method of claim 1 , wherein R′ and R″ are each hydrogen.

20. The method of claim 18 , wherein R′ and R″ are each hydrogen.

21. The method of claim 14 , wherein R 4 and R 5 are each hydrogen.

22. The method of claim 14 , wherein R′ and R″ are each hydrogen.

23. The method of claim 21 , wherein R′ and R″ are each hydrogen.

Assignees

• Univ California

Inventors

• Acharya Abhinav P
• Murthy Niren
• Woods Elliot C

Classifications

• A61K31/69

  Boron compounds · CPC title

• A61K45/06 Primary

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title